Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01006980
First received: October 30, 2009
Last updated: December 18, 2012
Last verified: December 2012
Results First Received: July 29, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Malignant Melanoma
Interventions: Drug: RO5185426
Drug: dacarbazine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
675 patients were randomized, 337 to vemurafenib and 338 to dacarbazine. One patient randomized to dacarbazine was treated in error with vemurafenib throughout the study and is included in the Vemurafenib arm in the table below and for exposure and safety analyses but was included in the dacarbazine arm for efficacy analyses.

Reporting Groups
  Description
Vemurafenib Participants received continuous oral doses of Vemurafenib (RO5185426) 960 mg twice a day. Patients took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
Dacarbazine Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).

Participant Flow:   Overall Study
    Vemurafenib     Dacarbazine  
STARTED     338 [1]   337  
(Randomized)     337     338  
Treated     336 [1]   289  
COMPLETED     223 [2]   83  
NOT COMPLETED     115     254  
Progression                 89                 174  
Adverse Event                 12                 9  
Death                 6                 11  
Refused treatment                 4                 20  
Withdrawal by Subject                 2                 25  
Protocol Violation                 0                 2  
Patient/Investigator/medical decisions                 0                 6  
Randomization error                 1                 0  
Disqualified prior to treatment                 1                 7  
[1] Includes one patient who was randomized to dacarbazine but received vemurafenib in error.
[2] Completed indicates patients still receiving treatment at the time of the clinical cutoff date.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Vemurafenib Participants received continuous oral doses of Vemurafenib (RO5185426) 960 mg twice a day. Patients took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
Dacarbazine Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).
Total Total of all reporting groups

Baseline Measures
    Vemurafenib     Dacarbazine     Total  
Number of Participants  
[units: participants]
  337     338     675  
Age, Customized  
[units: participants]
     
< 65 years     244     270     514  
>=65 years     93     68     161  
Gender  
[units: participants]
     
Female     137     157     294  
Male     200     181     381  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: From randomization (initiated January 2010) to December 30 2010. Median follow-up time in the vemurafenib group was 3.75 months (range 0.3 to 10.8) and in the dacarbazine group was 2.33 months (range <0.1 to 10.3). ]

2.  Primary:   Progression-free Survival   [ Time Frame: From randomization (initiated January 2010) to December 30 2010. ]

3.  Secondary:   Participants With a Best Overall Response (BOR) of Complete Response or Partial Response   [ Time Frame: From randomization (initiated January 2010) until December 30, 2010 ]

4.  Secondary:   Duration of Response   [ Time Frame: From randomization (initiated in January 2010) until December 30, 2010. ]

5.  Secondary:   Time to Confirmed Response   [ Time Frame: From randomization (initiated January 2010) until December 30, 2010. ]

6.  Secondary:   Time to Treatment Failure   [ Time Frame: approximately 3 years ]

7.  Secondary:   Number of Participants With Adverse Events (AEs)   [ Time Frame: From randomization (initiated January 2010) until December 30, 2010. ]

8.  Secondary:   Pre and Post-dose Plasma Vemurafenib Concentration by Study Day   [ Time Frame: Plasma samples were collected before the morning dose (troughs) and 2-4 hours after the morning dose at the beginning of each cycle (Days 1, 22, 43, 64, 106, 148 and 190). ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Hoffman-LaRoche
phone: 800-821-8590


No publications provided by Hoffmann-La Roche

Publications automatically indexed to this study:


Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01006980     History of Changes
Other Study ID Numbers: NO25026, 2009-012293-12
Study First Received: October 30, 2009
Results First Received: July 29, 2011
Last Updated: December 18, 2012
Health Authority: United States: Food and Drug Administration